Haloperidol Richter

Haloperidol Richter is a prescription intramuscular injection containing the active ingredient haloperidol, a butyrophenone antipsychotic. Marketed in the European Union, this formulation delivers haloperidol in a sterile solution for rapid systemic absorption. It is classified under ATC code N05AD01 and works as a dopamine D2 receptor antagonist. The product is intended for use under medical supervision in appropriate clinical settings and may be administered by trained healthcare professionals.

Haloperidol Richter is indicated for several acute psychiatric conditions where rapid control of symptoms is required.

- Schizophrenia, particularly during acute exacerbations when rapid symptom control is needed. - Acute psychotic episodes associated with mood disorders or substance use, requiring swift intramuscular intervention. - Severe agitation or aggression that poses a risk to self or others, often in emergency or inpatient settings. - Tourette syndrome with disabling motor or vocal tics that have not responded adequately to oral therapy. - Pre‑operative sedation in patients with known psychotic disorders to reduce peri‑operative stress and emergence phenomena.

Side effects of Haloperidol Richter reflect its dopamine antagonism and can vary in frequency and severity.

Common: - Drowsiness or sedation, which may affect alertness and the ability to perform tasks requiring concentration. - Extrapyramidal symptoms such as tremor, muscular rigidity, akathisia, or dystonia, reflecting dopamine blockade in the nigrostriatal pathway. - Anticholinergic effects including dry mouth, constipation, blurred vision, and occasional urinary retention. - Headache, which may be mild to moderate in intensity and usually transient.

Serious: - Neuroleptic malignant syndrome, a rare but fatal reaction with high fever, muscle rigidity, autonomic instability, and altered mental status. - Tardive dyskinesia, a late‑onset movement disorder causing repetitive, involuntary facial or limb movements after prolonged use. - Severe cardiovascular effects such as marked hypotension, arrhythmias, or QT‑interval prolongation, increasing the risk of cardiac events. - Seizures, especially in patients with a history of epilepsy or other risk factors.

When prescribing Haloperidol Richter, clinicians should consider several precautions to minimize risks and ensure safe use.

- Assess cardiovascular status, especially for patients with known arrhythmias or low blood pressure. - Evaluate for a history of extrapyramidal reactions or tardive dyskinesia before initiating therapy. - Use caution in patients with hepatic or renal impairment, as metabolism and clearance may be altered. - Monitor pregnant or breastfeeding women closely; the safety profile in pregnancy is not well established. - Avoid abrupt discontinuation to reduce the chance of withdrawal or rebound psychosis.

Haloperidol Richter may interact with other medicines; recognizing these interactions helps prevent adverse effects or reduced efficacy.

Avoid: - Other dopamine antagonists or high‑potency antipsychotics, which can increase the risk of extrapyramidal symptoms and cardiac toxicity. - QT‑prolonging agents such as certain antiarrhythmics, macrolide antibiotics, or antimalarials, which may exacerbate cardiac conduction delays.

Use with caution: - CNS depressants (e.g., benzodiazepines, opioids) that may enhance sedation and respiratory depression. - Anticholinergic medications, which can compound dry mouth, constipation, and blurred vision. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) that may raise haloperidol plasma levels. - Medications that lower seizure threshold (e.g., bupropion, tramadol) may increase the risk of seizures when combined with haloperidol.